Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines.
The alteration of T helper 1 (TH1) and TH2 responses and related cell-mediated immunity has been supposed to be associated with the immunological pathogenesis in the development of schizophrenia. Increasing evidence suggested the alteration of cytokines in accordance with the antipsychotic treatment as well, so that this study aimed at investigating the aberration of TH1 and -2 cytokines before and after antipsychotic treatment in patients with schizophrenia. Thirty-five schizophrenic patients with antipsychotic naïve or free more than 2 months participated in the study. We measured the plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-2 (TH1), and IL-6, IL-10 and IL-13 (TH2) at the time of admission and after an 8-week antipsychotic treatment. The IL-6 (p = 0.001) and -13 (p = 0.004) levels were significantly decreased after antipsychotic treatment than those of before antipsychotic treatment. The total and general PANSS score changes were correlated with the change of IL-6 (r = 0.598, corrected p < 0.05; r = 0.550, corrected p = 0.005, respectively). The baseline IL-6 level was correlated with change of general PANSS score (r = 0.449, corrected p = 0.044), whereas changes of other PANSS scores were not correlated with any other baseline cytokine levels. The baseline total PANSS score was correlated with the baseline levels of IL-13 (r = 0.776, corrected p < 0.005). The baseline total and general PANSS scores were correlated with the baseline levels of IL-6 (r = 0.689, corrected p < 0.005; r = 0.653, corrected p < 0.005). The correlations between the baseline levels of cytokines and the duration of illness and the age at onset were not found. Our study supports that TH-2 arm cytokines may be involved in the improvement of psychopathology and symptomatologies of schizophrenia and that antipsychotic drugs may suppress some TH-2 cytokines in patients with schizophrenia.
Pae
Chi-Un
CU
Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seocho-Gu, Seoul.
Yoon
Chong-Hyeon
CH
Kim
Tae-Suk
TS
Kim
Jung-Jin
JJ
Park
Sung-Hwan
SH
Lee
Chang-Uk
CU
Lee
Soo-Jung
SJ
Lee
Chul
C
Paik
In-Ho
IH
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D007377:Interleukin-3 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy / Q000276:immunology*; D012565:Schizophrenic Psychology; D018417:Th1 Cells / Q000187:drug effects / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects* / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics
D014150:Antipsychotic Agents; D016207:Cytokines; D007377:Interleukin-3; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha